Overview

A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B

Status:
Completed
Trial end date:
2017-12-08
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe and the United States of America. The aim of this trial is to compare the pharmacokinetics (the exposure of the trial drug in the body) of nonacog beta pegol (N9-GP) and ALPROLIX® in patients with haemophilia B.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S